Document 2697
 DOCN  M94A2697
 TI    Evaluation of Cambridge Biotech western blot kit.
 DT    9412
 AU    Senyonga P; Kataaha; Nakasero Blood Bank, Kampala-Uganda.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):245 (abstract no. PB0408). Unique
       Identifier : AIDSLINE ICA10/94369878
 AB    OBJECTIVES: To assess the suitability of the kit for HIV1 + 2
       confirmation. MATERIALS: The kit was submitted for evaluation by the
       company representative, clearly labelled with: the manufacturers
       address, to be used for HIV1 + 2 testing, contents and quantities,
       storage temperature and expiry date. 26 frozen, Elisa tested and Inno
       Lia blotted samples were tested. METHODS: Manufacturers recommended
       method was used to test the samples and the 4 controls supplied by the
       company. RESULTS: TABULAR DATA, SEE ABSTRACT VOLUME. RESULTS ANALYSIS:
       In addition to P24, cambridge Biotech detected ENV. 160 probably early
       sero conversion in the two samples. DISCUSSION: Clear instructions and
       easy to carry out, specificity and sensitivity comparable to that of
       Innolia. The detection of ENV. 160/120 is an added advantage, indicative
       of early sero-conversion.
 DE    *AIDS Serodiagnosis  *Blotting, Western  Comparative Study  Gene
       Products, env/IMMUNOLOGY  Human  HIV Core Protein p24/IMMUNOLOGY  HIV
       Seropositivity/*DIAGNOSIS/IMMUNOLOGY  HIV-1/*IMMUNOLOGY
       HIV-2/*IMMUNOLOGY  Predictive Value of Tests  Protein
       Precursors/IMMUNOLOGY  Reagent Kits, Diagnostic  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).